Should we stop taking thiazides to prevent kidney stones?

Published Date: 08 Mar 2023

"Thiazide is the standard treatment for calcium stones, so this [new research] has the potential to upset the basket," one observer said.

Read Full News

Latest News

German Government to Abandon Variable Drug Discounting Plans, Source Tells Reuters

Germany's government is replacing plans that would have introduced variable discounts on pharmaceuticals, ⁠a government source told Reuters on Monday, following opposition...

Male Fertility Not Harmed by GLP-1s and Maybe Helped

A systematic review finds no consistent adverse effects on the male hypothalamic-pituitary-gonadal axis and some evidence of fertility improvement with GLP-1 use.

Does Tirzepatide Activate Brown Fat?

Tirzepatide seems to activate brown adipose tissue, potentially modulating energy expenditure at the tissue level in premenopausal women with obesity.

Distinct Courses in Primary and Secondary Empty Sella

Patients with primary and secondary empty sella show distinct clinical and endocrine trajectories over a median follow-up of about 5 years.

Tirzepatide May Reverse Postbariatric Weight Regain

Tirzepatide treatment yields substantial weight loss and is well tolerated in patients with recurrent weight gain after bariatric procedures, a small real-world observational study finds.

Semaglutide Linked to Fewer Fractures

In contrast to concerns of lean mass loss with GLP-1 receptor agonists, a large population-based study found lower fracture rates with semaglutide than with other weight-loss medications.

Todays Updates

Multiple Myeloma Patients Have Unequal Access to Treatment

Lack of access to innovative and effective treatments compromises survival outcomes for many patients in Europe with multiple myeloma.

e-Cigarettes and Lung Cancer: Is Harm Reduction Overstated?

A large study links the use of e-cigarettes after smoking cessation to higher lung cancer incidence and mortality than complete nicotine abstinence.

Combination Treatment May Improve Multiple Myeloma Outcomes

Post hoc analysis of the MajesTEC-3 trial shows the efficacy of the teclistamab plus daratumumab combination in hard-to-treat patients with high cytogenetic and functional risk.

Is There a Role for Stimulants in Beating Cancer Fatigue?

Guidelines on treating cancer fatigue offer little enthusiasm for methylphenidate and other stimulants. But a recent meta-analysis suggests the medications deserve a rethink.

Todays Updates

Multiple Myeloma Patients Have Unequal Access to Treatment

Lack of access to innovative and effective treatments compromises survival outcomes for many patients in Europe with multiple myeloma.

e-Cigarettes and Lung Cancer: Is Harm Reduction Overstated?

A large study links the use of e-cigarettes after smoking cessation to higher lung cancer incidence and mortality than complete nicotine abstinence.

Combination Treatment May Improve Multiple Myeloma Outcomes

Post hoc analysis of the MajesTEC-3 trial shows the efficacy of the teclistamab plus daratumumab combination in hard-to-treat patients with high cytogenetic and functional risk.

Is There a Role for Stimulants in Beating Cancer Fatigue?

Guidelines on treating cancer fatigue offer little enthusiasm for methylphenidate and other stimulants. But a recent meta-analysis suggests the medications deserve a rethink.

Latest News

Germany's government is replacing plans that would have introduced variable discounts on pharmaceuticals, ⁠a government source told Reuters on Monday, following opposition...

A systematic review finds no consistent adverse effects on the male hypothalamic-pituitary-gonadal axis and some evidence of fertility improvement with GLP-1 use.

Tirzepatide seems to activate brown adipose tissue, potentially modulating energy expenditure at the tissue level in premenopausal women with obesity.

Patients with primary and secondary empty sella show distinct clinical and endocrine trajectories over a median follow-up of about 5 years.

Tirzepatide treatment yields substantial weight loss and is well tolerated in patients with recurrent weight gain after bariatric procedures, a small real-world observational study finds.

In contrast to concerns of lean mass loss with GLP-1 receptor agonists, a large population-based study found lower fracture rates with semaglutide than with other weight-loss medications.

News All Time

Novo Nordisk Flags Patient Data Breach From Some Clinical Trials in Cyberattack

Novo Nordisk said on Thursday it has identified a security incident in which certain information, including ⁠patient data from some clinical trials, was copied externally...

Tirzepatide Outperforms Conventional Care in Early Diabetes

Tirzepatide offered better glycemic control and greater weight loss than intensive conventional care in adults with early type 2 diabetes, a study finds.

AI-Guided Prep Improves Bariatric Surgery Consults

A structured, AI-supported metacognitive framework substantially enhances the quality of metabolic and bariatric surgery consultations.

PMOS: Insulin Resistance Affects Fertility and Pregnancy

Prepregnancy insulin resistance is associated with impaired fertility and increased pregnancy complications such as preeclampsia.

Over-the-Counter CGM Okayed for Kids

The US FDA extended the age of use for Dexcom’s Stelo down to 2 years.

Novel Oral GLP-1 Shows A1c and Weight-Loss Benefits

The new drug would add another oral GLP-1 with no fasting or fluid intake restrictions to clinicians’ toolboxes, improving options for targeted treatment.

Older Drug Reprograms White Blood Cells, Improves Blood Sugar in Type 1 Diabetes

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.)

Oral GLP-1 Orforglipron Performs Well in Phase 3 T2D Trials

Phase 3 trials of the oral nonpeptide show glycemic and weight benefit when added to glargine and compared with dapagliflozin and oral semaglutide, but with somewhat lower tolerability.

GLP-1s Tied to Musculoskeletal Benefits in Obesity

Use of GLP-1s vs other antiobesity medications is linked to decreased risk for osteoporosis, fractures, disk degeneration, and osteoarthritis in adults with obesity.

AI Tool Detects Occult Pancreatic Cancer Months in Advance

A new AI model reliably identifies hidden pancreatic ductal adenocarcinoma on routine CT scans months before the clinical diagnosis of the disease.

Use Of GLP-1 Drugs Early in Pregnancy Should Not Cause Alarm, Analysis Suggests

Use of GLP-1 drugs for diabetes or obesity early in the first trimester of pregnancy, before a woman realizes she is pregnant, is ⁠not a cause for alarm, a large new data...

Study Finds No Link Between Semaglutide and AMD Risk

Compared with other glucose-lowering drugs, semaglutide is not associated with the risk for neovascular age-related macular degeneration in adults with type 2 diabetes.

Can GLP-1s Curb Cancer Progression?

A real-world analysis links GLP-1s to substantially lower rates of metastatic progression in four cancers associated with obesity and/or diabetes — but experts urged caution to interpret the findings.

Skin Disorders in Transgender Patients: Treatment Tips

Dermatologists highlight the risks for acne, hair loss and unwanted hair, and melasma, as well as recent data on hidradenitis suppurativa.

Weekly and Monthly Berobenatide Show Weight, A1c Benefits

The long-acting GLP-1 drug had good overall tolerability with some GI bumps in weekly-to-monthly transition, while the A1c benefits raise hopes of a potential ‘game changer’ for T2D.

Roche Obesity Drug Helps Patients Shed 22.7% Of Weight in Mid-stage Trial

Roche said on Friday that patients lost 22.7% of their body weight in a mid-stage trial of its dual-acting experimental obesity ⁠drug, with more than a quarter of those who...

Recommended News For You

Paging Dr. AI; Myth Busting in Cancer; Oncologists Shine in Malpractice Survey

If CD19 CAR T-Cell Therapy Fails in Lymphoma, Try a CD22 Version

Emicizumab in Infants With Hemophilia A: Safe and Effective Use.

A computer-aided diagnostic system for improved detection of breast cancer.

According to a study, there is now a 94 percent survival rate for children with acute lymphatic leukemia.

A promising medication could slow brain tumors in children.

An FDA panel supports the use of CAR T-cell therapy earlier in the treatment of multiple myeloma.

Recommended Articles For You

Unlocking the Mystery of Hemoglobin C Trait: A Closer Look at a Rare Blood Disorder 

Unlocking the Potential of Lutathera: A Revolutionary Cancer Treatment 

What You Need to Know About Correcting Calcium Levels in Patients with Low Albumin  

Understanding Hidrocystoma: Symptoms, Causes, and Treatment Options  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Enthusiasm for Transplant-Free Strategies for Low-Risk Relapsed Hodgkin Lymphoma

2.

Life quality after childhood cancer is quantifiable thanks to outcome indicators.

3.

Muscular strength and good physical fitness linked to lower risk of death in people with cancer

4.

Study reveals link between new-onset type 2 diabetes and some obesity-related cancers

5.

No Gestational Diabetes-Cancer Link; Cholesterol and Cancer; Oncologist Saves Umpire

1.

Essential Techniques in Hematology for Better Care

2.

HSC Failure in Fanconi Anemia: Mechanisms, Models, and Emerging Therapeutic Pathways

3.

Mastering Prostate Cancer Care: CME, Certification, Digital Tools, and Evidence-Based Strategies

4.

Innovative Bioengineering Approaches for Erectile Function Recovery After Radical Prostatectomy

5.

The latest research on Iron Binding Capacity: The Little-Known Factor That Could Impact Your Health v

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

2.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

3.

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

4.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management

5.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot